Targeted Oncology Staff Writer

During a Targeted Oncology Case Based Peer Perspective event, Corey J. Langer, MD, discussed options for a 63-year-old patient with stage III non–small cell lung cancer.

Laura M. Kulik, MD, talked through diagnosing a 77-year-old female patients with hepatocellular carcinoma as well as the treatment options for her disease during a Targeted Oncology Case Based Peer Perspectives event.

The use of chemoimmunotherapy as treatment of patients with treatment-naive stage IIIB or IV nonsquamous non–small cell lung cancer was the topic of a Targeted Oncology Case Based Peer Perspective discussion led by Charu Aggarwal, MD, MPH.

During a Targeted Oncology Case Based Peer Perspective event, Anna C. Pavlick, DO, MS, MBA, discussed the case of a 69-year-old patient with cutaneous squamous cell carcinoma.

During a Targeted Oncology Case Based Peer Perspective event, Chung-Han Lee, MD, PhD, discussed the case of a 57-year-old woman with clear cell renal cell carcinoma.

During a Targeted Oncology Case Based Peer Perspective event, Usama Gergis, MD, MBA, and Scott D. Rowley, MD, reviewed the case of a 35-year-old woman with moderate chronic graft-versus-host disease.

During a Targeted Oncology Case Based Peer Perspectives event, Ghasson K. Abou-Alfa, MD, reviewed the case of a 77-year old woman with hepatocellular carcinoma.

The FDA granted approval to luspatercept-aamt as treatment of adult patients with anemia failing an erythropoiesis stimulating agent that requires 2 or more red blood cell units over 8 weeks, that is associated with very low- to intermediate-risk myelodysplastic syndromes, intermediate-risk myelodysplastic syndromes with ring sideroblasts or myelodysplastic/myeloproliferative neoplasm.

Combining a broad-spectrum tyrosine kinase inhibitor with an immune checkpoint inhibitor resulted in a high disease control rate in a preliminary dose-finding trial involving patients with advanced clear cell renal cell carcinoma.

A fourth of patients with advanced clear cell renal cell carcinoma responded to single-agent therapy with an oral hypoxia-inducible factor–2α inhibitor, which achieved a disease control rate of 80%, a preliminary clinical trial showed.

Men with metastatic castration-resistant prostate cancer had inferior immune responses with the combination of sipuleucel-T and radium-223 but improved clinical outcomes as compared with sipuleucel-T alone, a small randomized trial showed.

The FDA has granted approval to injectable pemetrexed for the treatment of patients with locally advanced or metastatic nonsquamous non–small cell lung cancer and for those with malignant pleural mesothelioma.

In a preliminary clinical trial, ARQ 531, an investigational Bruton tyrosine kinase inhibitor, showed safety and clinical activity across a variety of B-cell malignancies.

Adult patients&nbsp;with&nbsp;deleterious or suspected deleterious&nbsp;germline&nbsp;<em>BRCA</em>-mutated metastatic pancreatic adenocarcinoma who have not had disease progression on at least 16 weeks of first-line platinum-based chemotherapy may now receive maintenance therapy with the&nbsp;PARP inhibitor olaparib, according to an approval from the FDA.

According to a pooled analysis of neoadjuvant trials presented at the San Antonio Breast Cancer Symposium, a&nbsp;pathologic complete response to HER2-directed neoadjuvant therapy reduced the risk of recurrence in patients with early HER2-positive breast cancer but did not eliminate it, supporting the common practice of continued anti-HER2 therapy.

Patients with relapsed/refractory follicular lymphoma showed durable responses with the combination of polatuzumab-vedotin, obinutuzumab, and lenalidomide, according to results presented at the 2019 ASH Annual Meeting.

In a Targeted Oncology live case-based peer perspectives discussion, Mark Agulnik, MD, and Simon S. Yoo, MD, discussed with a group of physicians the staging criteria and the options for treatment for patients with cutaneous squamous cell carcinoma.

During a Targeted Oncology live case-based peer perspectives discussion, Matthew A. Gubens, MD, MS, reviewed with a group of physicians the localized and systemic treatment options available for the management of patients with non&ndash;small cell lung cancer.<br /> &nbsp;

Joyce A. O&rsquo;Shaughnessy, MD, led a group of physicians at a recent Targeted Oncology live case-based peer perspective event in discussion on emerging data that could affect treatment options for patients with triple-negative breast cancer in the future.

Bemcentinib, a first-in-class AXL inhibitor, in combination with the PD-1 inhibitor&nbsp;pembrolizumab showed activity in patients with immunotherapy-naive&nbsp;advanced&nbsp;non&ndash;small cell lung cancer, according to findings from the phase II study presented at the 2019 World Conference on Lung Cancer.

A statistically significant improvement in overall survival was demonstrated with durvalumab, a PD-L1 inhibitor, combined with chemotherapy in patients with previously untreated extensive-stage small cell lung cancer, according to findings from the phase III CASPIAN trial, presented at the 2019 World Conference on Lung Cancer.

During a&nbsp;Targeted Oncology&nbsp;case-based peer perspectives presentation, Ajai Chari, MD, discussed with a group of physicians the treatment options available to patients with relapsed multiple myeloma. Chari explained the various treatment options and the supporting data based around a case scenario of a patient with multiple myeloma who relapses.

At a recent&nbsp;Targeted Oncology&nbsp;live case-based peer perspectives event, Kanwal P. S. Raghav, MBBS, MD, presented a case scenario of a patient with colorectal cancer who has already gone through first- and second-line treatments. Raghav explained the treatment considerations he would make with similar patients in the clinic and the treatment options available to this patient with CRC in this setting.

A new drug application for tazemetostat, an EZH2 inhibitor,&nbsp;has been granted a priority review by the FDA for the treatment of patients with metastatic or locally advanced epithelioid sarcoma not eligible for curative surgery&nbsp;based on data from the&nbsp;epithelioid sarcoma cohort of a phase II trial.

Catherine Frenette, MD, explained in a&nbsp;Targeted Oncology&nbsp;live case-based peer perspectives presentation how she treats patients with hepatocellular carcinoma across the course of disease.

The first regulatory approval has been granted to entrectinib in Japan. The Japanese&nbsp;Ministry of Health, Labour and Welfare recently&nbsp;approved the agent for the treatment of adult and pediatric patients with&nbsp;<em>NTRK&nbsp;</em>fusion&ndash;positive, advanced recurrent solid tumors.

A novel immunotherapy agent has demonstrated significant survival rates for patients with metastatic uveal melanoma, according to updated results released at the 2018 ASCO Annual Meeting.